Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Debt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on Invested CapitalReturn on Sales

Dr Reddys Laboratories (RDY) Equity Average (2017 - 2020)

Historic Equity Average for Dr Reddys Laboratories (RDY) over the last 14 years, with Q3 2023 value amounting to $1.5 billion.

  • Dr Reddys Laboratories' Equity Average changed N/A to $1.5 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $1.5 billion, marking a year-over-year change of. This contributed to the annual value of $3.7 billion for FY2025, which is 1824.61% up from last year.
  • Dr Reddys Laboratories' Equity Average amounted to $1.5 billion in Q3 2023.
  • In the past 5 years, Dr Reddys Laboratories' Equity Average ranged from a high of $2.3 billion in Q4 2020 and a low of $956.9 million during Q1 2019
  • Its 5-year average for Equity Average is $1.5 billion, with a median of $1.4 billion in 2022.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 1473146.44% in 2019, then surged by 698.65% in 2020.
  • Over the past 5 years, Dr Reddys Laboratories' Equity Average (Quarter) stood at $2.1 billion in 2019, then rose by 9.4% to $2.3 billion in 2020, then crashed by 49.15% to $1.2 billion in 2021, then grew by 5.22% to $1.2 billion in 2022, then grew by 22.26% to $1.5 billion in 2023.
  • Its Equity Average stands at $1.5 billion for Q3 2023, versus $1.5 billion for Q2 2023 and $1.2 billion for Q2 2022.